Auxeris Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
Auxeris Therapeutics is using the cytokine RANK and its ligand as a drug target to identify anabolic bone-growth compounds.
You may also be interested in...
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.
Harbingers For IPF Drug Development
Roche’s decision to discontinue a Phase III program in idiopathic pulmonary fibrosis was the latest of several recent late-stage clinical failures, emblematic of the difficulty in finding new approaches to treat the disease.